Copaxone Promos Can’t List Risks Product Doesn’t Have, Especially Incorrectly, FDA Warns
This article was originally published in The Pink Sheet Daily
Executive Summary
The first warning letter of the year from FDA’s Office of Prescription Drug Promotion goes to Teva for web pages and materials displayed at a medical conference that overstated the safety and efficacy of its MS drug Copaxone.